open access

Vol 66, No 5 (2016)
Review articles
Published online: 2017-03-29
Get Citation

Proton radiotherapy for treating the most common carcinomas

Beata Sas-Korczyńska, Jerzy Jakubowicz, Marian Reinfuss
DOI: 10.5603/NJO.2016.0070
·
Nowotwory. Journal of Oncology 2016;66(5):396-402.

open access

Vol 66, No 5 (2016)
Review articles
Published online: 2017-03-29

Abstract

A literature review is presented on proton radiotherapy when used for treating the most common carcinoma types such as cancer of the lung, breast and prostate. This is based on analytic parameters of dosimetry and clinical outcomes (efficacy and toxicity), along with studies on cost-effectiveness as compared to those achieved by conventional photon radiotherapy.

Abstract

A literature review is presented on proton radiotherapy when used for treating the most common carcinoma types such as cancer of the lung, breast and prostate. This is based on analytic parameters of dosimetry and clinical outcomes (efficacy and toxicity), along with studies on cost-effectiveness as compared to those achieved by conventional photon radiotherapy.

Get Citation

Keywords

proton radiotherapy, lung cancer, breast cancer, prostate cancer

About this article
Title

Proton radiotherapy for treating the most common carcinomas

Journal

Nowotwory. Journal of Oncology

Issue

Vol 66, No 5 (2016)

Pages

396-402

Published online

2017-03-29

DOI

10.5603/NJO.2016.0070

Bibliographic record

Nowotwory. Journal of Oncology 2016;66(5):396-402.

Keywords

proton radiotherapy
lung cancer
breast cancer
prostate cancer

Authors

Beata Sas-Korczyńska
Jerzy Jakubowicz
Marian Reinfuss

References (113)
  1. Thariat J, Hannoun-Levi JM, Sun Myint A, et al. Past, present, and future of radiotherapy for the benefit of patients. Nat Rev Clin Oncol. 2013; 10(1): 52–60.
  2. Paganetti H, van Luijk P. Biological considerations when comparing proton therapy with photon therapy. Semin Radiat Oncol. 2013; 23(2): 77–87.
  3. Uhl M, Herfarth K, Debus J. Comparing the use of protons and carbon ions for treatment. Cancer J. 2014; 20(6): 433–439.
  4. Jiang GL. Particle therapy for cancers: a new weapon in radiation therapy. Front Med. 2012; 6(2): 165–172.
  5. LAWRENCE JH, TOBIAS CA, BORN JL, et al. Pituitary irradiation with high-energy proton beams: a preliminary report. Cancer Res. 1958; 18(2): 121–134.
  6. Levy RP, Fabrikant JI, Frankel KA, et al. Proton irradiation of the pituitary. Cancer. 1957; 10(4): 795–798.
  7. WILSON RR. Radiological use of fast protons. Radiology. 1946; 47(5): 487–491.
  8. Shirai T, Furukawa T, Inaniwa T, et al. Recent progress of new cancer therapy facility at HIMAC. Proc IPAC2011. 2011: 3604–3606.
  9. Suit H, DeLaney T, Goldberg S, et al. Proton vs carbon ion beams in the definitive radiation treatment of cancer patients. Radiother Oncol. 2010; 95(1): 3–22.
  10. www.ptcog.com.
  11. Jermann M. Particle Therapy Statistics in 2014. International Journal of Particle Therapy. 2015; 2(1): 50–54.
  12. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2): 87–108.
  13. Zatoński W, Sulkowska U, Didkowska J. Kilka uwag o epidemiologii nowotworów w Polsce. Nowotwory. Journal of Oncology. 2015; 65(3): 179–196.
  14. Wojciechowska U, Didkowska J, Zatoński W. Nowotwory złośliwe w Polsce w 2012 roku. Krajowy Rejestr Nowotworów, Warszawa 2014.
  15. Jett JR, Schild SE, Keith RL, et al. American College of Chest Physicians. Treatment of non-small cell lung cancer, stage IIIB: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007; 132(3 Suppl): 266S–276S.
  16. Bradley J, Graham MV, Winter K, et al. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys. 2005; 61(2): 318–328.
  17. Onishi H, Araki T, Shirato H, et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer. 2004; 101(7): 1623–1631.
  18. Partridge M, Ramos M, Sardaro A, et al. Dose escalation for non-small cell lung cancer: analysis and modelling of published literature. Radiother Oncol. 2011; 99(1): 6–11.
  19. Hayman JA, Martel MK, Ten Haken RK, et al. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. J Clin Oncol. 2001; 19(1): 127–136.
  20. Curran WJ, Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011; 103(19): 1452–1460.
  21. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999; 17(9): 2692–2699.
  22. Schild SE, Stella PJ, Geyer SM, et al. North Central Cancer Treatment Group. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol. 2003; 21(17): 3201–3206.
  23. Chang JY, Zhang X, Wang X, et al. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006; 65(4): 1087–1096.
  24. Curran WJ, Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011; 103(19): 1452–1460.
  25. Hoppe BS, Huh S, Flampouri S, et al. Double-scattered proton-based stereotactic body radiotherapy for stage I lung cancer: a dosimetric comparison with photon-based stereotactic body radiotherapy. Radiother Oncol. 2010; 97(3): 425–430.
  26. Macdonald OK, Kruse JJ, Miller JM, et al. Proton beam radiotherapy versus three-dimensional conformal stereotactic body radiotherapy in primary peripheral, early-stage non-small-cell lung carcinoma: a comparative dosimetric analysis. Int J Radiat Oncol Biol Phys. 2009; 75(3): 950–958.
  27. Wang C, Nakayama H, Sugahara S, et al. Comparisons of dose-volume histograms for proton-beam versus 3-D conformal x-ray therapy in patients with stage I non-small cell lung cancer. Strahlenther Onkol. 2009; 185(4): 231–234.
  28. Register SP, Zhang X, Mohan R, et al. Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011; 80(4): 1015–1022.
  29. Nichols RC, Huh SN, Henderson RH, et al. Proton radiation therapy offers reduced normal lung and bone marrow exposure for patients receiving dose-escalated radiation therapy for unresectable stage iii non-small-cell lung cancer: a dosimetric study. Clin Lung Cancer. 2011; 12(4): 252–257.
  30. Nakayama H, Satoh H, Sugahara S, et al. Proton beam therapy of Stage II and III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011; 81(4): 979–984.
  31. Bush DA, Cheek G, Zaheer S, et al. High-dose hypofractionated proton beam radiation therapy is safe and effective for central and peripheral early-stage non-small cell lung cancer: results of a 12-year experience at Loma Linda University Medical Center. Int J Radiat Oncol Biol Phys. 2013; 86(5): 964–968.
  32. Iwata H, Murakami M, Demizu Y, et al. High-dose proton therapy and carbon-ion therapy for stage I non-small cel lung cancer. Cancer. 2010; 116: 2476–2485.
  33. Bush DA, Slater JD, Shin BB, et al. Hypofractionated proton beam radiotherapy for stage I lung cancer. Chest. 2004; 126(4): 1198–1203.
  34. Hata M, Tokuuye K, Kagei K, et al. Hypofractionated high-dose proton beam therapy for stage I non-small-cell lung cancer: preliminary results of a phase I/II clinical study. Int J Radiat Oncol Biol Phys. 2007; 68(3): 786–793.
  35. Nihei K, Ogino T, Ishikura S, et al. High-dose proton beam therapy for Stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006; 65(1): 107–111.
  36. Nakayama H, Sugahara S, Tokita M, et al. Proton beam therapy for patients with medically inoperable stage I non-small-cell lung cancer at the university of tsukuba. Int J Radiat Oncol Biol Phys. 2010; 78(2): 467–471.
  37. Nakayama H, Satoh H, Sugahara S, et al. Proton beam therapy of Stage II and III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011; 81(4): 979–984.
  38. Hatayama Y, Nakamura T, Suzuki M, et al. Clinical outcomes and prognostic factors of high-dose proton beam therapy for peripheral stage I non-small-cell lung cancer. Clin Lung Cancer. 2016; 11: 5–10.
  39. Makita C, Nakamura T, Takada A, et al. High-dose proton beam therapy for stage I non-small cell lung cancer: Clinical outcomes and prognostic factors. Acta Oncol. 2015; 54(3): 307–314.
  40. Sejpal S, Komaki R, Tsao A, et al. Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer. Cancer. 2011; 117(13): 3004–3013.
  41. Chang JY, Komaki R, Lu C, et al. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer. 2011; 117(20): 4707–4713.
  42. Oshiro Y, Mizumoto M, Okumura T, et al. Results of proton beam therapy without concurrent chemotherapy for patients with unresectable stage III non-small cell lung cancer. J Thorac Oncol. 2012; 7(2): 370–375.
  43. Hatayama Y, Nakamura T, Suzuki M, et al. Preliminary results of proton-beam therapy for stage III non-small-cell lung cancer. Curr Oncol. 2015; 22(5): e370–e375.
  44. Hoppe BS, Henderson R, Pham D, et al. A Phase 2 Trial of Concurrent Chemotherapy and Proton Therapy for Stage III Non-Small Cell Lung Cancer: Results and Reflections Following Early Closure of a Single-Institution Study. Int J Radiat Oncol Biol Phys. 2016; 95(1): 517–522.
  45. Gomez DR, Gillin M, Liao Z, et al. Phase 1 study of dose escalation in hypofractionated proton beam therapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013; 86(4): 665–670.
  46. Bush DA, Slater JD, Shin BB, et al. Hypofractionated proton beam radiotherapy for stage I lung cancer. Chest. 2004; 126(4): 1198–1203.
  47. Bonnet RB, Bush D, Cheek GA, et al. Effects of proton and combined proton/photon beam radiation on pulmonary function in patients with resectable but medically inoperable non-small cell lung cancer. Chest. 2001; 120(6): 1803–1810.
  48. Hoppe BS, Henderson R, Pham D, et al. Proton therapy with concurrent chemotherapy for non-small-cell lung cancer: technique and early results. Clin Lung Cancer. 2012; 13(5): 352–358.
  49. Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst. 1996; 88(17): 1210–1215.
  50. Kong FM, Ten Haken RK, Schipper MJ, et al. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys. 2005; 63(2): 324–333.
  51. Aupérin A, Le Péchoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010; 28(13): 2181–2190.
  52. Cox JD. Are the results of RTOG 0617 mysterious? Int J Radiat Oncol Biol Phys. 2012; 82(3): 1042–1044.
  53. Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015; 16(2): 187–199.
  54. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. The Lancet. 2005; 366(9503): 2087–2106.
  55. Darby S, McGale P, Correa C, et al. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011; 378(9804): 1707–1716.
  56. McGale P, Taylor C, Correa C, et al. EBCTCG (Early Breast Cancer Trialists' Collaborative Group). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014; 383(9935): 2127–2135.
  57. Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013; 368(11): 987–998.
  58. Offersen B, Højris I, Overgaard M. Radiation-induced heart morbidity after adjuvant radiotherapy of early breast cancer - Is it still an issue? Radiother Oncol. 2011; 100(2): 157–159.
  59. Curigliano G, Cardinale D, Suter T, et al. ESMO Guidelines Working Group. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012; 23 Suppl 7: 155–166.
  60. Gagliardi G, Constine LS, Moiseenko V, et al. Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys. 2010; 76(3 Suppl): S77–S85.
  61. Darby SC, McGale P, Taylor CW, et al. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol. 2005; 6(8): 557–565.
  62. Shah C, Badiyan S, Berry S, et al. Cardiac dose sparing and avoidance techniques in breast cancer radiotherapy. Radiother Oncol. 2014; 112(1): 9–16.
  63. Xu N, Ho MW, Li Z, et al. Can proton therapy improve the therapeutic ratio in breast cancer patients at risk for nodal disease? Am J Clin Oncol. 2014; 37(6): 568–574.
  64. Ares C, Khan S, Macartain AM, et al. Postoperative proton radiotherapy for localized and locoregional breast cancer: potential for clinically relevant improvements? Int J Radiat Oncol Biol Phys. 2010; 76(3): 685–697.
  65. MacDonald SM, Jimenez R, Paetzold P, et al. Proton radiotherapy for chest wall and regional lymphatic radiation; dose comparisons and treatment delivery. Radiat Oncol. 2013; 8: 71.
  66. Fogliata A, Bolsi A, Cozzi L. Critical appraisal of treatment techniques based on conventional photon beams, intensity modulated photon beams and proton beams for therapy of intact breast. Radiother Oncol. 2002; 62(2): 137–145.
  67. Ares C, Khan S, Macartain AM, et al. Postoperative proton radiotherapy for localized and locoregional breast cancer: potential for clinically relevant improvements? Int J Radiat Oncol Biol Phys. 2010; 76(3): 685–697.
  68. Moon SHo, Shin KH, Kim TH, et al. Dosimetric comparison of four different external beam partial breast irradiation techniques: three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, helical tomotherapy, and proton beam therapy. Radiother Oncol. 2009; 90(1): 66–73.
  69. Johansson J, Isacsson U, Lindman H, et al. Node-positive left-sided breast cancer patients after breast-conserving surgery: potential outcomes of radiotherapy modalities and techniques. Radiother Oncol. 2002; 65(2): 89–98.
  70. Orecchia R, Fossati P, Zurrida S, et al. New frontiers in proton therapy: applications in breast cancer. Curr Opin Oncol. 2015; 27(6): 427–432.
  71. Fagundes M, Hug E, Pankuch M, et al. Proton Therapy for Local-regionally Advanced Breast Cancer Maximizes Cardiac Sparing. International Journal of Particle Therapy. 2015; 1(4): 827–844.
  72. Xu N, Ho MW, Li Z, et al. Can proton therapy improve the therapeutic ratio in breast cancer patients at risk for nodal disease? Am J Clin Oncol. 2014; 37(6): 568–574.
  73. Cuaron JJ, Chon B, Tsai H, et al. Early toxicity in patients treated with postoperative proton therapy for locally advanced breast cancer. Int J Radiat Oncol Biol Phys. 2015; 92(2): 284–291.
  74. Bradley JA, Dagan R, Ho MW, et al. Initial Report of a Prospective Dosimetric and Clinical Feasibility Trial Demonstrates the Potential of Protons to Increase the Therapeutic Ratio in Breast Cancer Compared With Photons. Int J Radiat Oncol Biol Phys. 2016; 95(1): 411–421.
  75. Jimenez RB, Goma C, Nyamwanda J, et al. Intensity modulated proton therapy for postmastectomy radiation of bilateral implant reconstructed breasts: a treatment planning study. Radiother Oncol. 2013; 107(2): 213–217.
  76. Mast ME, Vredeveld EJ, Credoe HM, et al. Whole breast proton irradiation for maximal reduction of heart dose in breast cancer patients. Breast Cancer Res Treat. 2014; 148(1): 33–39.
  77. Lin LL, Vennarini S, Dimofte A, et al. Proton beam versus photon beam dose to the heart and left anterior descending artery for left-sided breast cancer. Acta Oncol. 2015; 54(7): 1032–1039.
  78. Correa CR, Litt HI, Hwang WT, et al. Coronary artery findings after left-sided compared with right-sided radiation treatment for early-stage breast cancer. J Clin Oncol. 2007; 25(21): 3031–3037.
  79. Marks LB, Yu X, Prosnitz RG, et al. The incidence and functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys. 2005; 63(1): 214–223.
  80. Flejmer A, Nyström P, Dohlmar F, et al. Potential Benefit of Scanned Proton Beam versus Photons as Adjuvant Radiation Therapy in Breast Cancer. International Journal of Particle Therapy. 2015; 1(4): 845–855.
  81. Bush DA, Do S, Lum S, et al. Partial breast radiation therapy with proton beam: 5-year results with cosmetic outcomes. Int J Radiat Oncol Biol Phys. 2014; 90(3): 501–505.
  82. Galland-Girodet S, Pashtan I, MacDonald SM, et al. Long-term cosmetic outcomes and toxicities of proton beam therapy compared with photon-based 3-dimensional conformal accelerated partial-breast irradiation: a phase 1 trial. Int J Radiat Oncol Biol Phys. 2014; 90(3): 493–500.
  83. Chang JiH, Lee NK, Kim JaY, et al. Phase II trial of proton beam accelerated partial breast irradiation in breast cancer. Radiother Oncol. 2013; 108(2): 209–214.
  84. MacDonald SM, Patel SA, Hickey S, et al. Proton therapy for breast cancer after mastectomy: early outcomes of a prospective clinical trial. Int J Radiat Oncol Biol Phys. 2013; 86(3): 484–490.
  85. Taghian AG, Kozak KR, Katz A, et al. Accelerated partial breast irradiation using proton beams: Initial dosimetric experience. Int J Radiat Oncol Biol Phys. 2006; 65(5): 1404–1410.
  86. Bush DA, Slater JD, Garberoglio C, et al. Partial breast irradiation delivered with proton beam: results of a phase II trial. Clin Breast Cancer. 2011; 11(4): 241–245.
  87. Hansen T, Bartlett G, Mannina E, et al. Dosimetric Comparison of Treatment Techniques: Brachytherapy, Intensity-Modulated Radiation Therapy, and Proton Beam in Partial Breast Irradiation. International Journal of Particle Therapy. 2015; 2(2): 376–384.
  88. Zietman AL, Bae K, Slater JD, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol. 2010; 28(7): 1106–1111.
  89. Cahlon O, Hunt M, Zelefsky MJ. Intensity-modulated radiation therapy: supportive data for prostate cancer. Semin Radiat Oncol. 2008; 18(1): 48–57.
  90. Cahlon O, Zelefsky MJ, Shippy A, et al. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys. 2008; 71(2): 330–337.
  91. Zietman AL, Chung CS, Coen JJ, et al. 10-year outcome for men with localized prostate cancer treated with external radiation therapy: results of a cohort study. J Urol. 2004; 171(1): 210–214.
  92. Kosaki K, Ecker S, Habermehl D, et al. Comparison of intensity modulated radiotherapy (IMRT) with intensity modulated particle therapy (IMPT) using fixed beams or an ion gantry for the treatment of patients with skull base meningiomas. Radiat Oncol. 2012; 7: 44.
  93. Paganetti H. Assessment of the risk for developing a second malignancy from scattered and secondary radiation in radiation therapy. Health Phys. 2012; 103(5): 652–661.
  94. Vargas C, Fryer A, Mahajan C, et al. Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2008; 70(3): 744–751.
  95. Nihei K, Ogino T, Onozawa M, et al. Multi-institutional Phase II study of proton beam therapy for organ-confined prostate cancer focusing on the incidence of late rectal toxicities. Int J Radiat Oncol Biol Phys. 2011; 81(2): 390–396.
  96. Mendenhall NP, Li Z, Hoppe BS, et al. Early outcomes from three prospective trials of image-guided proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2012; 82(1): 213–221.
  97. Schwarz M, Pierelli A, Fiorino C, et al. Helical tomotherapy and intensity modulated proton therapy in the treatment of early stage prostate cancer: a treatment planning comparison. Radiother Oncol. 2011; 98(1): 74–80.
  98. Talcott JA, Rossi C, Shipley WU, et al. Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer. JAMA. 2010; 303(11): 1046–1053.
  99. Slater JD, Rossi CJ, Yonemoto LT, et al. Proton therapy for prostate cancer: the initial Loma Linda University experience. Int J Radiat Oncol Biol Phys. 2004; 59(2): 348–352.
  100. Schulte RW, Slater JD, Rossi CJ, et al. Value and perspectives of proton radiation therapy for limited stage prostate cancer. Strahlenther Onkol. 2000; 176(1): 3–8.
  101. Slater JD, Rossi CJ, Yonemoto LT, et al. Proton therapy for prostate cancer: the initial Loma Linda University experience. Int J Radiat Oncol Biol Phys. 2004; 59(2): 348–352.
  102. Yu JB, Soulos PR, Herrin J, et al. Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. J Natl Cancer Inst. 2013; 105(1): 25–32.
  103. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005; 294(10): 1233–1239.
  104. Johansson S, Aström L, Sandin F, et al. Hypofractionated proton boost combined with external beam radiotherapy for treatment of localized prostate cancer. Prostate Cancer. 2012; 2012: 654861.
  105. Henderson RH, Hoppe BS, Marcus RB, et al. Urinary functional outcomes and toxicity five years after proton therapy for low- and intermediate-risk prostate cancer: results of two prospective trials. Acta Oncol. 2013; 52(3): 463–469.
  106. Kim YJ, Cho KHo, Pyo HR, et al. A phase II study of hypofractionated proton therapy for prostate cancer. Acta Oncol. 2013; 52(3): 477–485.
  107. Mendenhall NP, Hoppe BS, Nichols RC, et al. Five-year outcomes from 3 prospective trials of image-guided proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2014; 88(3): 596–602.
  108. Coen JJ, Bae K, Zietman AL, et al. Acute and late toxicity after dose escalation to 82 GyE using conformal proton radiation for localized prostate cancer: initial report of American College of Radiology Phase II study 03-12. Int J Radiat Oncol Biol Phys. 2011; 81(4): 1005–1009.
  109. Shipley WU, Verhey LJ, Munzenrider JE, et al. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys. 1995; 32(1): 3–12.
  110. Sheets NC, Goldin GH, Meyer AM, et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA. 2012; 307(15): 1611–1620.
  111. Hoppe BS, Michalski JM, Mendenhall NP, et al. Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer. Cancer. 2014; 120(7): 1076–1082.
  112. Vargas CE, Hartsell WF, Dunn M, et al. Hypofractionated Versus Standard Fractionated Proton-beam Therapy for Low-risk Prostate Cancer: Interim Results of a Randomized Trial PCG GU 002. Am J Clin Oncol. 2015 [Epub ahead of print].
  113. Verma V, Mishra MV, Mehta MP. A systematic review of the cost and cost-effectiveness studies of proton radiotherapy. Cancer. 2016; 122(10): 1483–1501.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media sp. z o.o. VM Group sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl